Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Vyxeos Market Size Growth Rate by Type
1.3.2 Daunorubicin 29 mg/m2 and Cytarabine 65 mg/m2
1.3.3 Daunorubicin 44 mg/m2 and Cytarabine 100 mg/m2
1.4 Market Segment by Application
1.4.1 Global Vyxeos Market Share by Application (2018-2025)
1.4.2 Hospital
1.4.3 Pharmacy
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Vyxeos Market Size
2.1.1 Global Vyxeos Revenue 2013-2025
2.1.2 Global Vyxeos Sales 2013-2025
2.2 Vyxeos Growth Rate by Regions
2.2.1 Global Vyxeos Sales by Regions 2013-2018
2.2.2 Global Vyxeos Revenue by Regions 2013-2018
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Vyxeos Sales by Manufacturers
3.1.1 Vyxeos Sales by Manufacturers 2013-2018
3.1.2 Vyxeos Sales Market Share by Manufacturers 2013-2018
3.2 Revenue by Manufacturers
3.2.1 Vyxeos Revenue by Manufacturers (2013-2018)
3.2.2 Vyxeos Revenue Share by Manufacturers (2013-2018)
3.2.3 Global Vyxeos Market Concentration Ratio (CR5 and HHI)
3.3 Vyxeos Price by Manufacturers
3.4 Key Manufacturers Vyxeos Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Vyxeos Market
3.6 Key Manufacturers Vyxeos Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Daunorubicin 29 mg/m2 and Cytarabine 65 mg/m2 Sales and Revenue (2013-2018)
4.1.2 Daunorubicin 44 mg/m2 and Cytarabine 100 mg/m2 Sales and Revenue (2013-2018)
4.2 Global Vyxeos Sales Market Share by Type
4.3 Global Vyxeos Revenue Market Share by Type
4.4 Vyxeos Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Vyxeos Sales by Application
6 North America
6.1 North America Vyxeos Breakdown Data by Company
6.2 North America Vyxeos Breakdown Data by Type
6.3 North America Vyxeos Breakdown Data by Application
6.4 North America Vyxeos Breakdown Data by Countries
6.4.1 North America Vyxeos Sales by Countries
6.4.2 North America Vyxeos Revenue by Countries
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
7 Europe
7.1 Europe Vyxeos Breakdown Data by Company
7.2 Europe Vyxeos Breakdown Data by Type
7.3 Europe Vyxeos Breakdown Data by Application
7.4 Europe Vyxeos Breakdown Data by Countries
7.4.1 Europe Vyxeos Sales by Countries
7.4.2 Europe Vyxeos Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 UK
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Vyxeos Breakdown Data by Company
8.2 Asia Pacific Vyxeos Breakdown Data by Type
8.3 Asia Pacific Vyxeos Breakdown Data by Application
8.4 Asia Pacific Vyxeos Breakdown Data by Countries
8.4.1 Asia Pacific Vyxeos Sales by Countries
8.4.2 Asia Pacific Vyxeos Revenue by Countries
8.4.3 China
8.4.4 Japan
8.4.5 Korea
8.4.6 India
8.4.7 Australia
8.4.8 Indonesia
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Thailand
8.4.12 Vietnam
9 Central & South America
9.1 Central & South America Vyxeos Breakdown Data by Company
9.2 Central & South America Vyxeos Breakdown Data by Type
9.3 Central & South America Vyxeos Breakdown Data by Application
9.4 Central & South America Vyxeos Breakdown Data by Countries
9.4.1 Central & South America Vyxeos Sales by Countries
9.4.2 Central & South America Vyxeos Revenue by Countries
9.4.3 Brazil
10 Middle East and Africa
10.1 Middle East and Africa Vyxeos Breakdown Data by Type
10.2 Middle East and Africa Vyxeos Breakdown Data by Application
10.3 Middle East and Africa Vyxeos Breakdown Data by Countries
10.3.1 Middle East and Africa Vyxeos Sales by Countries
10.3.2 Middle East and Africa Vyxeos Revenue by Countries
10.3.3 GCC Countries
10.3.4 Egypt
10.3.5 South Africa
11 Company Profiles
11.1 Celator Pharmaceuticals
11.1.1 Celator Pharmaceuticals Company Details
11.1.2 Company Description and Business Overview
11.1.3 Sales, Revenue and Market Share of Vyxeos
11.1.4 Vyxeos Product Introduction
11.1.5 Celator Pharmaceuticals Recent Development
11.2 Jazz Pharma
11.2.1 Jazz Pharma Company Details
11.2.2 Company Description and Business Overview
11.2.3 Sales, Revenue and Market Share of Vyxeos
11.2.4 Vyxeos Product Introduction
11.2.5 Jazz Pharma Recent Development
12 Value Chain and Sales Channels Analysis
12.1 Value Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Vyxeos Sales Channels
12.2.2 Vyxeos Distributors
12.3 Vyxeos Customers
13 Market Forecast
13.1 Global Vyxeos Sales and Revenue Forecast 2018-2025
13.2 Global Vyxeos Sales Forecast by Type
13.3 Global Vyxeos Sales Forecast by Application
13.4 Vyxeos Forecast by Regions
13.4.1 Global Vyxeos Sales Forecast by Regions 2018-2025
13.4.2 Global Vyxeos Revenue Forecast by Regions 2018-2025
13.5 North America Market Forecast
13.5.1 North America Vyxeos Forecast by Countries 2018-2025
13.5.2 United States
13.5.3 Canada
13.5.4 Mexico
13.6 Europe Market Forecast
13.6.1 Europe Vyxeos Forecast by Countries 2018-2025
13.6.2 Germany
13.6.3 France
13.6.4 UK
13.6.5 Italy
13.6.6 Russia
13.7 Asia Pacific Market Forecast
13.7.1 Asia Pacific Vyxeos Sales Forecast by Countries 2018-2025
13.7.2 China
13.7.3 Japan
13.7.4 Korea
13.7.5 India
13.7.6 Australia
13.7.7 Indonesia
13.7.8 Thailand
13.7.9 Malaysia
13.7.10 Philippines
13.7.11 Vietnam
13.8 Central & South America Market Forecast
13.8.1 Central & South America Vyxeos Sales Forecast by Countries 2018-2025
13.8.2 Brazil
13.9 Middle East and Africa Market Forecast
13.9.1 Middle East and Africa Vyxeos Sales Forecast by Countries 2018-2025
13.9.2 GCC Countries
13.9.3 Egypt
13.9.4 South Africa
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Celator Pharmaceuticals、Jazz Pharma
【免責事項】
https://www.globalresearch.jp/disclaimer